Drug Profile
Debamestrocel - BrainStorm Cell Therapeutics
Alternative Names: Autologous bone marrow derived mesenchymal stem cell therapy - BrainStorm Cell therapeutics; Autologous MSC-NTF; Bone-marrow-derived-mesenchymal-stem-cells-BrainStorm; GDNF therapy; GDNf-stem-cell-therapy-BrainStorm-Cell-Therapeutics; Glial-cell-line-derived-neurotrophic-factor-producing-adult-bone-marrow-derived-stem-cell-therapy-BrainStorm Cell Therapeutics; Glial-cell-line-derived-neurotrophic-factor-stem-cell-therapy-BrainStorm; MSC-NTF; MSC-NTF cell; MSC-NTF-BrainStorm-Cell-Therapeutics; Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics; Neurotrophic factor-secreting stem cell therapy; Neurotrophic-factor-producing-adult-stem-cell-therapy-BrainStorm; NurOwn; NurOwn-GDNF-therapy; NurOwn™ program oneLatest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Tel Aviv University
- Developer Brainstorm Cell Therapeutics; Hadassah Medical Organization; Tel Aviv University
- Class Exosome therapies; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Dopaminergic cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis
- Preclinical Acute lung injury; Huntington's disease; Parkinson's disease; Peripheral nerve injuries; Pervasive child development disorders
- No development reported Sciatica; Spinal cord injuries
Most Recent Events
- 09 Apr 2024 BrainStorm Cell Therapeutics receives agreement under special protocol assessment from the FDA for neurotrophic factor producing mesenchymal stem cell therapy in Amyotrophic lateral sclerosis
- 09 Apr 2024 Brainstorm Cell Therapeutics plans a phase IIIb trial for Amyotrophic lateral sclerosis in 2024
- 23 Feb 2024 BrainStorm Cell Therapeutics expects response on SPA from US FDA for Amyotrophic lateral sclerosis within 45 days from the date of submission